AIMS: In this double centre, retrospective study, we aimed to analyse the 1-year efficacy and safety of cryoballoon ablation (CB-A) in patients older than 75 years compared with those younger than 75-years old. METHODS AND RESULTS: Fifty-three consecutive patients aged 75 years or older with drug-resistant paroxysmal AF (PAF) who underwent pulmonary vein isolation (PVI) by the means of second generation CB-A, were compared with 106 patients aged <75 years. The mean age in the study group (>75 years) was 78.19 ± 2.7 years and 58.97 ± 8.5 in the control group. At 1-year follow-up the global success rate was 83.6% and did not significantly differ between older (10/53) and younger patients (16/106) (81.1 vs. 84.9%, P = 0.54). Transient phrenic nerve palsy was the most common complication which occurred in eight patients in the younger group and in three in the older group (7.5 vs. 5.7%, respectively, P = 0.66). CONCLUSIONS: The results of our study showed that CB-A for the treatment of PAF is a feasible and safe procedure in elderly patients, with similar success and complications rates when compared with a younger population. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: In this double centre, retrospective study, we aimed to analyse the 1-year efficacy and safety of cryoballoon ablation (CB-A) in patients older than 75 years compared with those younger than 75-years old. METHODS AND RESULTS: Fifty-three consecutive patients aged 75 years or older with drug-resistant paroxysmal AF (PAF) who underwent pulmonary vein isolation (PVI) by the means of second generation CB-A, were compared with 106 patients aged <75 years. The mean age in the study group (>75 years) was 78.19 ± 2.7 years and 58.97 ± 8.5 in the control group. At 1-year follow-up the global success rate was 83.6% and did not significantly differ between older (10/53) and younger patients (16/106) (81.1 vs. 84.9%, P = 0.54). Transient phrenic nerve palsy was the most common complication which occurred in eight patients in the younger group and in three in the older group (7.5 vs. 5.7%, respectively, P = 0.66). CONCLUSIONS: The results of our study showed that CB-A for the treatment of PAF is a feasible and safe procedure in elderly patients, with similar success and complications rates when compared with a younger population. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Thomas Fink; Andreas Metzner; Stephan Willems; Lars Eckardt; Hüseyin Ince; Johannes Brachmann; Stefan G Spitzer; Thomas Deneke; Claus Schmitt; Matthias Hochadel; Jochen Senges; Andreas Rillig Journal: Clin Res Cardiol Date: 2019-04-05 Impact factor: 5.460
Authors: Joerelle Mojica; Felicia Lipartiti; Maysam Al Housari; Gezim Bala; Shuichiro Kazawa; Vincenzo Miraglia; Cinzia Monaco; Ingrid Overeinder; Antanas Strazdas; Robbert Ramak; Gaetano Paparella; Juan Sieira; Lucio Capulzini; Antonio Sorgente; Erwin Stroker; Pedro Brugada; Carlo De Asmundis; Gian-Battista Chierchia Journal: J Atr Fibrillation Date: 2021-06-30
Authors: Luigi Sciarra; Saverio Iacopino; Giuseppe Arena; Claudio Tondo; Paolo Pieragnoli; Giulio Molon; Massimiliano Manfrin; Antonio Curnis; Antonio Dello Russo; Giovanni Rovaris; Giuseppe Stabile; Leonardo Calò; Gabriele Boscolo; Roberto Verlato Journal: Cardiol Res Pract Date: 2021-12-28 Impact factor: 1.866
Authors: Tauseef Akhtar; Ryan Wallace; Usama A Daimee; Bhradeev Sivasambu; Erica Hart; Eunice Yang; Joseph E Marine; Ronald Berger; Hugh Calkins; David Spragg Journal: Indian Pacing Electrophysiol J Date: 2021-11-25
Authors: Gaëlle Vermeersch; Juan-Pablo Abugattas; Varnavas Varnavas; Jeroen De Cocker; Bruno Schwagten; Juan Sieira; Carlo de Asmundis; Gian-Battista Chierchia; Yves De Greef Journal: J Arrhythm Date: 2021-03-26